Lilly's phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight | Eli Lilly and Company
The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.